Stock Track | Illumina Plunges 5.12% After-Hours as 2025 Revenue Forecast Disappoints

Stock Track

Feb 07, 2025

Illumina, a leading provider of gene sequencing machines and diagnostic tools, experienced a significant after-hours plunge of 5.12% on Thursday, February 6th, 2025. This decline followed the company's release of its 2025 revenue forecast, which largely fell short of Wall Street's expectations.

In its earnings report, Illumina projected annual revenue for 2025 to range between $4.28 billion and $4.4 billion. Analysts, on average, had estimated the company's 2025 revenue to be around $4.39 billion, indicating that Illumina's guidance missed market expectations.

The disappointing revenue forecast suggests subdued demand for Illumina's genetic tests and diagnostic tools, which could be attributed to reduced spending from biotech clients in recent years. While recent interest rate cuts may improve the funding environment for biotechs, it appears that Illumina is facing challenges in maintaining its growth momentum.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1106670268"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1106670268\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1106670268?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-07 05:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1106670268","market":"us","top_or_hot":-1,"title":"Stock Track | Illumina Plunges 5.12% After-Hours as 2025 Revenue Forecast Disappoints","media":"Stock Track","content":"<p>Illumina, a leading provider of gene sequencing machines and diagnostic tools, experienced a significant after-hours plunge of 5.12% on Thursday, February 6th, 2025. This decline followed the company's release of its 2025 revenue forecast, which largely fell short of Wall Street's expectations.</p>\n\n<p>In its earnings report, Illumina projected annual revenue for 2025 to range between $4.28 billion and $4.4 billion. Analysts, on average, had estimated the company's 2025 revenue to be around $4.39 billion, indicating that Illumina's guidance missed market expectations.</p>\n\n<p>The disappointing revenue forecast suggests subdued demand for Illumina's genetic tests and diagnostic tools, which could be attributed to reduced spending from biotech clients in recent years. While recent interest rate cuts may improve the funding environment for biotechs, it appears that Illumina is facing challenges in maintaining its growth momentum.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Illumina Plunges 5.12% After-Hours as 2025 Revenue Forecast Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Illumina Plunges 5.12% After-Hours as 2025 Revenue Forecast Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-02-07 05:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Illumina, a leading provider of gene sequencing machines and diagnostic tools, experienced a significant after-hours plunge of 5.12% on Thursday, February 6th, 2025. This decline followed the company's release of its 2025 revenue forecast, which largely fell short of Wall Street's expectations.</p>\n\n<p>In its earnings report, Illumina projected annual revenue for 2025 to range between $4.28 billion and $4.4 billion. Analysts, on average, had estimated the company's 2025 revenue to be around $4.39 billion, indicating that Illumina's guidance missed market expectations.</p>\n\n<p>The disappointing revenue forecast suggests subdued demand for Illumina's genetic tests and diagnostic tools, which could be attributed to reduced spending from biotech clients in recent years. While recent interest rate cuts may improve the funding environment for biotechs, it appears that Illumina is facing challenges in maintaining its growth momentum.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ILMN","symbol_name":"Illumina","start_time":0,"source_url":"","article_id":"1106670268","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1106670268","pubTimestamp":1738878158,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Illumina, a leading provider of gene sequencing machines and diagnostic tools, experienced a significant after-hours plunge of 5.12% on Thursday, February 6th, 2025. This decline followed the company's release of its 2025 revenue forecast, which largely fell short of Wall Street's expectations.In its earnings report, Illumina projected annual revenue for 2025 to range between $4.28 billion and $4.4 billion. Analysts, on average, had estimated the company's 2025 revenue to be around $4.39 billion","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ILMN":"Illumina"},"translate_title":"2025年收入预测令人失望，Illumina盘后暴跌5.12%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILMN":1},"content_text":"Illumina, a leading provider of gene sequencing machines and diagnostic tools, experienced a significant after-hours plunge of 5.12% on Thursday, February 6th, 2025. This decline followed the company's release of its 2025 revenue forecast, which largely fell short of Wall Street's expectations.\nIn its earnings report, Illumina projected annual revenue for 2025 to range between $4.28 billion and $4.4 billion. Analysts, on average, had estimated the company's 2025 revenue to be around $4.39 billion, indicating that Illumina's guidance missed market expectations.\nThe disappointing revenue forecast suggests subdued demand for Illumina's genetic tests and diagnostic tools, which could be attributed to reduced spending from biotech clients in recent years. While recent interest rate cuts may improve the funding environment for biotechs, it appears that Illumina is facing challenges in maintaining its growth momentum.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}